KR900006326A - 크로만 유도체 - Google Patents

크로만 유도체 Download PDF

Info

Publication number
KR900006326A
KR900006326A KR1019890014761A KR890014761A KR900006326A KR 900006326 A KR900006326 A KR 900006326A KR 1019890014761 A KR1019890014761 A KR 1019890014761A KR 890014761 A KR890014761 A KR 890014761A KR 900006326 A KR900006326 A KR 900006326A
Authority
KR
South Korea
Prior art keywords
formula
compound
carbon atoms
chromanol
cyano
Prior art date
Application number
KR1019890014761A
Other languages
English (en)
Other versions
KR0150780B1 (ko
Inventor
게릭커 롤프
바움가르트 만프레드
루에스 인게보르그
드페이어 야퀘스
베르그만 롤프
Original Assignee
위르겐 호이만, 라인 하르트 쉬틀러
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 호이만, 라인 하르트 쉬틀러, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁 filed Critical 위르겐 호이만, 라인 하르트 쉬틀러
Publication of KR900006326A publication Critical patent/KR900006326A/ko
Application granted granted Critical
Publication of KR0150780B1 publication Critical patent/KR0150780B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

내용 없음

Description

크로만 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 일반식(I)의 크로만 유도체 및 이의 염.
    상기 식에서, R1은 A이고, R2및 R8은 각기 H 또는 A이고, R1및 R2는 또한 함께 탄소수 3 내지 6을 갖는 알킬렌이고, R3는 H,OH,OA 또는 OAc이고, R4는 H이고, R3및 R4는 또한 함께 결합하고, R5는 비치환 또는 A, F, Cl, Br, I, OH, OA, OAc, SH, NO2, NH2AcNH, HOOC 및/또는 AOOC에 의해 일치환 또는 이치환된 피리딜, 피리다진일, 피리미딘일, 피라진일, 옥소디히드로피리딜, 옥소디히드로피리다진일, 옥소디히드로피리미딘일 또는 옥소디히로피라진일 라디칼이고, R6및 R7는 각기 H, A, HO, AO, CHO, ACO, ACS, HOOC, AOOC, AO-CS, ACOO, A-CS-O, 탄소수 1 내지 6을 갖는 히드록시알킬, 탄소수 1 내지 6 을 갖는 머캅토 알킬, NO2, NH2, NHA, NA2, CN, F, Cl, Br, I, CF3, ASO, ASO2, AO-SO, AO-SO2, AcNH, AO-CO-NH, H2NSO, HANSO, A2NCO, H2NSO2, HANSO2, A2NSO2, H2NCO, HANCO, A2NCO, H2NCS, HANCS, A2NCS, ASONH, ASO2NH, AOSONH, AOSO2NH, ACO-알킬, 니트로알킬, 시아노알킬, A-C(=NOH) 또는 A-C(=NNH2)이고, Z는 O,S 또는 NH이고, A는 탄소수 1 내지 6을 갖는 알킬이고, 알킬은 탄소수 1 내지 6을 갖는 알킬렌이고, Ac는 탄소수 1 내지 8을 갖는 알칸오일 또는 탄소수 7 내지 11을 갖는 아로일이다.
  2. a)2,2-디메틸-4-(2-히드록시-4-피리딜옥시)-6-시아노-3-크로만올, b)2,2,3-트리메틸-4-(2-히드록시-4-피리딜옥시)-6-시아노-3-크로만올, c)2,2-디메틸-4-(6-히드록시-3-피리다진일옥시)-6-시아노-3-크로만올, d) 2,2,3-트리메틸-4-(6-히드록시-4-피리다진일옥시)-6-시아노-3-크로만올, e) 2,2-디메틸-4-(1,6-디히드로-1-메틸-6-옥소-3-피리다진일옥시)-6-시아노-3-크로만올 ; f) 2,2,3-트리메틸-4-(1,6-디히드로-1-메틸-6-옥소-3-피리다진일옥시)-6-시아노-3-크로만올.
  3. 일반식(I)의 크로만 유도체의 제조방법에 있어서, 일반식(Ⅱ)의 크로만을
    (상기식에서, X-Y는또는 -CHE-CR3R8이고 E는 Cl, Br, I 또는 반응 에스테르화된 OH 그룹이고, R1,R2,R3,R6,R7및 R8은 일반식(I)에서 정의한 바와 같다) 일반식(Ⅲ)의 화합물.
    R5-ZH (Ⅲ)
    (상기식에서, R5및 Z는 일반식(I)에서 정의한 바와 같다)또는 이의 반응 유도체의 하나와 반응시키고/시키거나 일반식(I)(여기서, R3는 OH이고, R4는 H이다)의 화합물을 탈수시키고/시키거나 일반식(I)의 화합물에 있어서 라디칼 R3,R5,R6및/또는 R7중 하나 이상을 다른 라디칼 R3,R5,R6및/또는 R7으로 전환시키고/시키거나 일반식(I)의 기본 화합물을 산으로 처리시켜 이의 산 부가염중 하나로 전환시키는 것을 특징으로 하는 제 1 항에 따른 일반식(I)의 크로만유도체의 제조방법.
  4. 일반식(I)의 화합물 및/또는 이의 생리학적으로 허용가능한 염중 하나를 적어도 하나의 고형, 액형 또는 반고형 부형제 또는 보조제와 함께, 필요시 하나이상의 다른 활성화합물(들)과 조합시켜 적합한 투여형태로 제조하는 것을 특징으로 하는 약학적 제제의 제조방법.
  5. 적어도 하나의 일반식(I)의 화합물 및/또는 이의 생리학적으로 허용가능한 염중 하나를 함유하는 약학적 제제.
  6. 질병치료를 위한 일반식(I)의 화합물.
  7. 약품의 제조를 위한 일반식(I)의 화합물의 용도.
  8. 질병을 치료하는 데 있어서 일반식(I)의 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890014761A 1988-10-14 1989-10-14 크로만 유도체 KR0150780B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3835011.4 1988-10-14
DE3835011A DE3835011A1 (de) 1988-10-14 1988-10-14 Chromanderivate

Publications (2)

Publication Number Publication Date
KR900006326A true KR900006326A (ko) 1990-05-07
KR0150780B1 KR0150780B1 (ko) 1998-10-15

Family

ID=6365113

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890014761A KR0150780B1 (ko) 1988-10-14 1989-10-14 크로만 유도체

Country Status (14)

Country Link
EP (1) EP0363883A1 (ko)
JP (1) JP2874912B2 (ko)
KR (1) KR0150780B1 (ko)
AR (1) AR247743A1 (ko)
AU (1) AU628395B2 (ko)
DE (1) DE3835011A1 (ko)
DK (1) DK511089A (ko)
FI (1) FI92825C (ko)
HU (1) HU217812B (ko)
IL (1) IL91967A0 (ko)
NO (1) NO174422C (ko)
NZ (1) NZ231000A (ko)
PT (1) PT91979B (ko)
ZA (1) ZA897783B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
AU628331B2 (en) * 1988-05-06 1992-09-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
DE3924417A1 (de) * 1989-07-24 1991-01-31 Merck Patent Gmbh Chromanderivate
GB8924373D0 (en) * 1989-10-30 1989-12-20 Beecham Group Plc Novel compounds
DE4038752A1 (de) * 1990-12-05 1992-06-11 Merck Patent Gmbh Chromanderivate
JP3442815B2 (ja) * 1992-05-13 2003-09-02 第一製薬株式会社 ジアザビシクロアルケン誘導体
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
JP2001151767A (ja) * 1999-09-17 2001-06-05 Nissan Chem Ind Ltd ベンゾピラン誘導体
JP2001158780A (ja) * 1999-09-24 2001-06-12 Nissan Chem Ind Ltd ４−オキシベンゾピラン誘導体
JP2001172275A (ja) * 1999-10-05 2001-06-26 Nissan Chem Ind Ltd ４−オキシベンゾピラン誘導体
WO2007027780A2 (en) * 2005-09-01 2007-03-08 Janssen Pharmaceutica N.V. Benzopyran and pyranopyridine derivatives as potassium channel openers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8419515D0 (en) * 1984-07-31 1984-09-05 Beecham Group Plc Treatment
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
CH674984A5 (ko) * 1987-05-16 1990-08-15 Sandoz Ag
AU628331B2 (en) * 1988-05-06 1992-09-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
EP0346724A1 (de) * 1988-06-16 1989-12-20 MERCK PATENT GmbH Chromanderivate
DE3918041A1 (de) * 1989-06-02 1990-12-06 Merck Patent Gmbh Chromanderivate

Also Published As

Publication number Publication date
DE3835011A1 (de) 1990-04-19
HU895311D0 (en) 1990-01-28
FI894858A0 (fi) 1989-10-13
HUT58082A (en) 1992-01-28
PT91979B (pt) 1995-05-31
AU628395B2 (en) 1992-09-17
DK511089A (da) 1990-04-15
PT91979A (pt) 1990-04-30
ZA897783B (en) 1991-07-31
IL91967A0 (en) 1990-07-12
NZ231000A (en) 1992-02-25
NO894103D0 (no) 1989-10-13
EP0363883A1 (de) 1990-04-18
NO894103L (no) 1990-04-17
FI92825B (fi) 1994-09-30
AR247743A1 (es) 1995-03-31
JP2874912B2 (ja) 1999-03-24
KR0150780B1 (ko) 1998-10-15
AU4256589A (en) 1990-04-26
JPH02145584A (ja) 1990-06-05
NO174422C (no) 1994-05-04
DK511089D0 (da) 1989-10-13
HU217812B (hu) 2000-04-28
NO174422B (no) 1994-01-24
FI92825C (fi) 1995-01-10

Similar Documents

Publication Publication Date Title
KR880007507A (ko) 크로만 유도체
KR890017246A (ko) 크로만 유도체
DK139287A (da) Tertiaere hydroxyalkylxanthiner, deres fremstilling og anvendelse som laegemidler
KR900006326A (ko) 크로만 유도체
KR890002060A (ko) 옥사졸리디논 화합물
KR910000711A (ko) 크로만 유도체
KR890016036A (ko) 아스코르브산 2-포스페이트 에스테르
KR910009272A (ko) 메일라아드 반응의 억제를 위한 제약조성물 및 방법
KR910004602A (ko) 크로만 유도체
KR900007798A (ko) 테트랄린 유도체
RU2000128648A (ru) Комплексные соединения платины, способы их получения и фармацевтическая композиция
KR910000713A (ko) 크로만 유도체
KR860008157A (ko) 2.5-디아릴 테트라하이드로푸란 및 이의 동족체의 제조방법
KR910002845A (ko) 크로만 유도체
KR910020006A (ko) 옥사졸리디논
KR910002842A (ko) 크로만 유도체
KR920012073A (ko) 크로만 유도체
KR940003953A (ko) 1. 4-벤조디옥산 유도체
KR910021400A (ko) 옥사졸리디논
EP0366561A3 (fr) Nouveaux dérivés 1-azabicycloalkanes, leur procédé de préparation et leur application comme médicaments
DK230082A (da) Carbacykliner fremgangsmaade til deres fremstilling og deres anvendelse som laegemiddel
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
KR910007907A (ko) 크로만 유도체
KR900007835A (ko) 벤즈옥사진 유도체
KR890005113A (ko) 아자크로만 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee